This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Dovato
  • /
  • An Efficacy, Safety, and Tolerability Study Compar...
Clinical trial

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Read time: 1 mins
Last updated:20th Apr 2020
Status: Active, not recruiting
Identifier: NCT02831673
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

This study will compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily with DTG plus two nucleoside reverse transcriptase inhibitors (Tenofovir [TDF]/Emtricitabine [FTC] fixed dose combination [FDC]) administered once daily in human immunodeficiency virus (HIV) 1 infected adult subjects that have not previously received antiretroviral therapy. The study is designed to demonstrate the non-inferior antiviral activity of DTG plus 3TC regimen to that of DTG plus TDF/FTC FDC and will characterise the long term antiviral activity, tolerability and safety of DTG plus 3TC through Week 148. Approximately, 700 subjects will be randomised 1:1 to receive DTG + 3TC or DTG + TDF/FTC FDC. Subjects will be stratified by screening HIV 1 ribonucleotide nucleic acid (RNA) levels and by screening CD4+ (cluster of differentiation 4) cell count.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 719 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Actual Study Start Date: July 21, 2016
Actual Primary Completion Date: March 29, 2018
Estimated Study Completion Date: March 4, 2024

Arm:
- Experimental:
DTG + 3TC (50 mg+300 mg)
- Active Comparator: DTG + TDF/FTC FDC (50 mg+300/200 mg)

Category Value
Study type(s) Interventional
Expected enrolment 719
Study start date 21 July 2016
Estimated study completion date 04 March 2024

View full details